Kornimate/medical-research-clean huggingface dataset:
the efficacy of complete mesocolic excision with central vessel ligation technique on lymph nodes and safety margins compared with conventional surgery for colon cancer treatment

Conditions: Cancer Colon

Summary: cancer colon is one of the major public health problems worldwide. complete eradication of the tumor with no recurrence or residual masses is a challenge which faces all the surgeons and medical staff all over the world. a lot of techniques were used to ensure 100 % eradication of the tumor and to cure the patients from cancer. total mesocolic excision with central vessel ligation is one of the recent techniques used for colon cancer surgeries. here in the research the investigators answer the question of how this technique is superior and more beneficial in complete eradication of the tumor than the conventional surgery for colon cancer


Eligibility criteria:
inclusion criteria: * • adult male and female age of or above 18 years. * tumor localization at the caecum, ascending colon, transverse colon, descending colon, sigmoid colon or rectosigmoid on preoperative endoscopy and radiographic imaging \[barium enema or computed tomography (ct)\] * no history of familial adenomatous polyposis, ulcerative colitis or crohn's disease * written informed consent exclusion criteria: * • contraindications to major surgery and american society of anaesthesiologists (asa) physical status scoring 4 which means extreme systemic disorders which have already become an eminent threat to life regardless of the type of treatment. * infectious disease requiring treatment. * pregnant women * use of systemic steroids. * severe pulmonary emphysema or pulmonary fibrosis

Keywords: cancer colon
benefit of esp peri operative analgesia for live liver donor transplantation

Conditions: Liver Transplant Disorder

Summary: liver donors have a significant risk to develop persistent and chronic pain around 20 to 30% affecting social and professional life (17%) up to 1 year after the surgery. to donate a part of liver is a beautiful gift reason why the pain relief must be improved. meta-analysis showed that the best prevention against post operative chronic pain are the techniques blocking the pain signal (regional anaesthesia) patients after liver donation are still in pain even in 2020 with the best multimodal analgesia medications. erector sinae plane block (esp) esp will block the signal and improve the pain relief we hope to demonstrate that it will reduce the risk to develop post operative chronic pain and improve the quality of recovery and the quality of life after liver donation

1. goals: compare quality of pain relief and quality of life between bilateral esp bilateral catheters vs opioid analgesia in donor patients for liver donation. 2. methodology: • selection criteria: age \> 18 years old be volunteer to donate liver agree to participate in the trial • exclusion criteria: use of chronic opioids contra-indication tom perform esp catheter (infection near puncture point, severe thoracic scoliosis, allergie to local anesthestics) a diagnosis of a chronic pain conditiondepression or other psychiatric diagnosis • study design: prospective randomized controlled trial. patients who agree to join the study will be randomized into 2 groups: group 1 (control group): standard of care in liver donation : intraoperative analgesia by opioid sufentanil and post operative analgesia by pca opioid morphine group 2 (treatement group): standard peri-operative analgesia for liver donation in since investigators use regional anaesthesia as first line treatement for peri operative analgesia bilateral esp catheters with continuous regional analgesia by infusion of local anesthestic (ropivacaine) sample size: investigators expected to increase the quality of life (qol) score (using under-the-curve area) from 36·9 for the eras group to 38.3 for esp group the sample size of 10 patients per group is required to detect such changes assuming a confidence interval of 95% with a power of 90% and alpha = 0.05. considering 20% of drop-out, the total sample size is 24 patients (12 patients each group) 3. project outcomes: * primary outcomes quality of pain relief with opioid consumption * secondary outcomes duration of hospitalisation participants satisfaction quality of recovery (qor 16) pain at 1 \& 3 months rest and mobilization + qol

Eligibility criteria:
inclusion criteria: * age more than 18 and less than 61 * be volunteer to donate liver * agree to participate to study and consent signed * risk of americain society of anesthesiologists score asa from 1 to 5 score asa must be 1 only exclusion criteria: * use of chronic opioid before the surgery * a diagnosis of chronic pain condition * contra indication to perform esp catheter * allergy to local anesthestics * depression or psychiatric diagnosis
geriatric lateral compression 1 pelvic fractures

Conditions: Lateral Compression 1 Pelvic Fracture

Summary: lateral compression-1 (lc1) pelvic ring fragility fractures cause significant pain and morbidity. these fragility injuries are associated with prolonged immobility and long hospital stays. currently there is no consensus on operative stabilization of lc1 pelvic fractures, nor are there evidence-based guidelines to aid in management of these injury types. furthermore, there is variability in operative indications, improvement in pain and mobilization. the purpose of this study is to compare percutaneous screw fixation to non-operative management in symptomatic lc1 fragility fractures in elderly patients.

this study is a prospective, randomized control trial (rct) of 100 patients with fragility pelvic ring fractures. all patients presenting with pelvic ring fractures classified as lc1 confirmed with plain radiographs, ct and/or mri, resulting from a low energy mechanism or an insufficiency fracture without a precipitating event will undergo a trial of physical therapy with mobilization and multimodal pain management. if the subject has substantial posterior pelvic pain (score ≥ 7 with the visual analogue scale (vas)) or inability to ambulate after the physical therapy trial for 48 hours, the subject is eligible for enrollment in the rct. patients will either be grouped into an operative group, defined as percutaneous screw fixation, or a nonoperative group, defined as treatment with physical therapy and pain management only. 1. group 1-operative treatment: percutaneous screw fixation will be performed for stabilization of the pelvic fracture 2. group 2-conservative (non-operative) treatment: pain management and physical therapy advanced with weight bearing as tolerated.

Eligibility criteria:
inclusion criteria: * patients \>/= 60 years of age * lateral compression 1 pelvic ring fractures confirmed with plain radiographs, ct and/or mri * low energy mechanism of injury or an insufficiency fracture without a precipitating event * acute injury within four weeks of presentation * inability or significant pain to mobilize with physical therapy assistance for 48 hours: significant pain as determined by a pain score ≥ 7 with the visual analogue scale (vas) after a timed "up \& go" (tug) assessment, or inability to complete the tug assessment. exclusion criteria: * dementia * vertically or rotationally unstable pelvic ring injuries * pathologic fracture secondary to tumor * non-ambulatory prior to injury * acute neurologic deficit * high-energy mechanism of injury * concomitant injuries affecting ambulation * presence of another injury or medical condition that prevents ambulation * presence of implant or sacral morphology that prevents percutaneous sacral fixation * enrollment in another research study the precludes co-enrollment * likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, etc.) * incarcerated or pending incarceration

Keywords: lateral compression operative non-operative fragility fracture pelvic fracture percutaneous pelvis screw osteoporosis
beats 2: music therapy in sickle cell

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to investigate the effects of the beats music therapy program on the self-efficacy, trust, knowledge, and adherence of young adult patients with scd. primary hypotheses: compared to baseline, young adult patients with scd who receive the music therapy interventions will report: higher sickle cell self-efficacy as measured by the sickle cell self efficacy scale (scses), higher trust in health care providers as measured by the wake forest trust in the medical profession scale, and higher scd knowledge as measured by the seidman sickle cell knowledge quiz. secondary hypotheses compared to the one year prior to the study period, young adults with scd who receive the music therapy interventions will have a higher rate of adherence to clinic appointments during the one-year study period. additional questions do music therapy interventions influence the rate of hospital utilization as measured by ed visits, acute care clinic (acc) visits, and admissions during the study period compared to the previous year? do music therapy interventions influence adherence to hydroxyurea therapy for patients receiving hydroxyurea as measured by change in mean corpuscular volume (mcv) during the study period? do music therapy interventions influence adherence to iron chelation therapy for patients receiving iron chelation therapy as measured by ferritin count during the study period? does the schedule of music therapy interventions in this study improve outcomes more significantly than the schedule of music therapy interventions from \[irb# 03-15-30\]?


Eligibility criteria:
inclusion criteria: * subject is between 18 and 35 years of age * subject is diagnosed with sickle cell disease * subject is able to speak and understand english * subject has a working email address. * subject has access to a mobile device with email capabilities. exclusion criteria: * subject has significant hearing impairment that has not been corrected * subject has significant visual impairment that has not been corrected
walking dynamic among children with brain damge

Conditions: Traumatic Brain Injury; Cerebral Palsy

Summary: the goal of the present study was to look at the effect of changing walking parameters on the dynamic walking characteristics among children post severe traumatic brain injury, children with cerebral palsy and typically developed controls.

leisure time physical activity by the godin and shephard (g\&s) questionnaire. balance tests - the timed up and go test (tug) and functional reach test (frt). maximal isometric strength was assessed by using a hand held dynamometer; walking dynamics were recorded by an electronic mat, and the 6 minute walk test, energy expenditure index (eei) and perceived exertion by the omni scale.

Eligibility criteria:
inclusion criteria: post traumatic brain injury * post severe closed head injury (glasgow coma scale (gcs) score at admission to emergency room of ≤8 * at least one year post trauma * ages 7 to 13 years * independent ambulation (foot orthoses permitted) children with cerebral palsy * gmfcs 1 or 2 * ages 7 to 13 years * able to stand up from a chair independently and maintain standing for more than 5 seconds without falling, without obvious limitation in the passive range of motion of lower extremities. typically developed age and sex controls exclusion criteria: * children who could not fulfill simple instructions

Keywords: walking performance cerebral palsy, typically developed
single dose of tranexamic acid and blood loss, in elderly patients with hip fracture

Conditions: Blood Loss, Surgical; Hip Fractures; Complication, Postoperative

Summary: the aim of this study is to investigate the hypothesis that single dose of tranexamic acid (txa) preoperatively will lower blood loss and transfusion rate in elderly patients with hip fractures (intertrochanteric or subcapital), that will be treated with intramedullary nailing and cemented hemiarthroplasty respectively. after application of inclusion and exclusion criteria, patients will be randomized in two groups. group 1 will include patients that receive preoperatively single dose of txa (15mg/kg) and group 2 will include patients that receive normal saline (control group).


Eligibility criteria:
inclusion criteria: * consecutive elderly patients (age \>75 yo) undergoing hip fracture surgery for a stable or unstable intertrochanteric hip fracture with the insertion of a short intramedullary nail (imn) as well as patients treated surgically with cemented hemiarthroplasty for acute femoral neck (subcapital) hip fracture. exclusion criteria: * any contraindication for tranexamic acid * multiple fractures * requirement for anticoagulant therapy that could not be stopped. * ongoing thromboembolic event * reduced kidney function * malignancy, * pathological fracture * previous operation on the affected hip * active coronary artery disease (event in the past 12 months).

Keywords: tranexamic acid blood tranfusion hip fractures elderly blood loss
a gene hunting study for familial papillary thyroid cancer

Conditions: Thyroid

Summary: the aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (ptc). papillary thyroid cancer is a type of cancer that shows high heritability. however, the specific genetic factors that cause an increased risk have been elusive.

the aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (ptc). this can be accomplished in several ways, including loss of heterozygosity studies as well as comparative gene expression analysis. when possible, linkage analysis on families with multiple individuals affected with ptc may also help identify the putative gene(s). study participants will be asked to: 1. complete family history and medical history questionnaires 2. sign a medical record release so that thyroid cancer pathology reports can be obtained 3. supply a blood or saliva sample for genetic studies 4. provide study related information to family members who are needed for family studies

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of ptc and a family history of ptc in 3 or more living relatives * affected and unaffected family members of the proband\* * for familial cases (families with 4 or more cases of ptc), participation will be offered to all living family members with ptc or benign thyroid disease as well as selected unaffected first and second degree relatives. participation may also be offered to spouses when needed for analyzing parent/offspring samples. exclusion criteria: * known germline predisposition (ex: pathogenic pten variant) * non-english speaking

Keywords: papillary carcinoma gene hunting familial
therapy for people with opioid use disorder

Conditions: Opioid Use Disorder

Summary: the goal of this pilot clinical trial is to test the feasibility of a 12-week manualized cognitive-behavioral therapy treatment for opioid use disorder in reducing or stopping illicit opioid use in a community setting. participants will complete 12 weeks of therapy with a behavioral health counselor and will complete assessments at baseline and 12 weeks. other outcomes include changes in mood and perceptions of recovery-related support after 12 weeks of therapy.

cognitive-behavioral therapy (cbt) is one of the most well-supported and widely used psychosocial treatments for substance use disorders (suds); however, few studies have evaluated the efficacy of cbt for opioid use disorder (oud). this prospective, longitudinal pilot study (pre-post design) will assess the feasibility of the first manualized cbt treatment for oud in adults (n = 20) in a community-based setting (prevention point philadelphia). this study will utilize clinical (urinalysis), patient-reported, and provider-reported outcomes (mood, support, feasibility, satisfaction with treatment) over 12 weeks of a manualized cognitive-behavioral treatment for oud. this prospective, longitudinal pilot study will evaluate the feasibility of a novel psychotherapy for oud. this study will utilize both clinical (urinalysis) and patient or provider-reported (mood, support, feasibility) outcomes to assess the feasibility of 12 weeks of manualized cognitive-behavioral treatment for oud. all study recruitment, consent and intervention delivery will occur at prevention point (2913-15 kensington ave, philadelphia, pa). outcomes will include participant-reported treatment satisfaction, as well as emr-extracted clinical data (session attendance, urinalysis, mood, demographics, medical information, and recovery-related support). we hypothesize that individuals with oud will demonstrate a reduction illicit opioid use from baseline to week 12 as assessed by urinalysis (% change, positive/negative). as a secondary outcome, use of other substances will also be assessed from baseline to week 12 (e.g., alcohol, cocaine). use of medication for oud (moud; e.g., buprenorphine. methadone) will be accounted for in analyses. we hypothesize that mood and perceptions of recovery-related resources will improve from baseline to week 12. as an exploratory aim, we will evaluate intervention feasibility through electronic medical record (emr) data of number of sessions attended over 12 weeks, treatment fidelity checklists, and a participant survey of treatment satisfaction.

Eligibility criteria:
inclusion criteria: * patient at prevention point philadelphia * 18 years or older * living with opioid use disorder * has a goal to reduce or eliminate illicit opioid use * able to provide informed consent exclusion criteria: * not comfortable receiving psychotherapy in english * under custodial supervision through the legal justice system (e.g., halfway house following incarceration, involuntary detention or confinement, status as a "prisoner")
study evaluating tse-424/placebo/raloxifene in preventing osteoporosis in postmenopausal women

Conditions: Osteoporosis

Summary: the purpose of this study is to determine whether tse-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.

primary objective: to evaluate the safety and efficacy of 3 doses of tse-424 (bazedoxifene acetate), an investigational drug, in comparison with those of placebo and raloxifene in preventing osteoporosis in postmenopausal women. secondary objective: to evaluate the effect of tse-424 (bazedoxifene acetate), an investigational drug, in comparison with that of placebo and raloxifene on endometrium, metabolic parameters, vasomotor symptoms, adverse events, and quality of life. samples will be collected for population pharmacokinetic (pk) analysis.

Eligibility criteria:
inclusion criteria: * generally healthy women 45 years of age or older who are at least 1 year postmenopausal. * subjects must qualify for one of the following categories (a or b): a) greater than 1 year but less than 5 years postmenopausal with at least one of the osteoporosis risk factors. b) greater than 5 years postmenopausal with bmd t-score at lumbar spine or femoral neck between -1 and -2.5 (inclusive) with at least one osteoporosis risk factor. exclusion criteria: * one (1) or more osteoporotic vertebral fractures (t4-l4). * diseases that may affect bone metabolism. * past history or active nontraumatic venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.

Keywords: postmenopausal osteoporosis
antipsychotic effects of probiotics and prebiotics on patients with schizophrenia

Conditions: Schizophrenia

Summary: in this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment, gastrointestinal function, and metabolic disorders in schizophrenia patients, through genotype identification, psychopathology, neuropsychology, biochemical evaluation and other methods.

the study will recruit 210 schizophrenia patients who meet the criteria of dsm-4, and then randomized to 3 groups: control group, probiotics group and prebiotics group for a 14-weeks clinical trail and 12-weeks follow-up period. in addition to probiotics, prebiotic or maltodextrin interventions, in the meantime, all participants will also use one of the prescribed antipsychotics medications. clinical efficacy and safety assessment will be done at baseline, clinical trail and follow-up period. the specific aims are to evaluate these tips: 1) psychotic syndrome; 2) cognition; 3) gastrointestinal function; 4) inflammatory and metabolic related markers. psychotic syndrome will be measured by the positive and negative syndrome scale. cognitive function will be assessed by the matrics consensus cognitive battery. gastrointestinal function will be assessed by gastrointestinal symptom assessment scale (gsrs). biological samples also will be collected, and stored to research intestinal inflammation, intestinal permeability, intestinal flora and other indicators.

Eligibility criteria:
inclusion criteria: * meet the diagnostic and statistical manual (dsm-v) diagnostic criteria for schizophrenia * duration of illness 5 years, subjects are currently receiving first-line recommended antipsychotic medication * the total panss score ≥60, containing at least three positive or negative items with scores of 3 or more at screening * junior high school or above * capacity for written informed consent. exclusion criteria: * pregnant or lactating women * any clinically significant or unstable medical disorder as determined by the investigators, including congestive heart failure, abnormal liver function, renal failure, immunodeficiency diseases, cancer, or gastrointestinal diseases ( inflammatory bowel disease or celiac disease, except functional constipation) * subjects had acute or chronic infections or are taking anti-inflammatory drugs and cortisol hormones. receipt of antibiotic medication within the previous 1 month. * other neuropsychiatric disorders (organic diseases of the central nervous system, a mental disorder caused by a physical disease or psychoactive substance, mental retardation). * having history of substance dependence or abuse，including alcohol * bmi is not within the normal range (18.5 to 23.9)

Keywords: schizophrenia probiotics